To evaluate the competing pro-haemorrhagic contribution of acquired von Willebrand (vW) disease and antithrombotic therapy in patients implanted with continuous-flow left ventricular assist devices (LVADs).
Bleeding in patients with continuous-flow left ventricular assist devices: acquired von Willebrand disease or antithrombotics?
Redaelli, Alberto;
2022-01-01
Abstract
To evaluate the competing pro-haemorrhagic contribution of acquired von Willebrand (vW) disease and antithrombotic therapy in patients implanted with continuous-flow left ventricular assist devices (LVADs).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2022_Consolo_EJCTS.pdf
Open Access dal 01/11/2023
Dimensione
941.01 kB
Formato
Adobe PDF
|
941.01 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
